Ebola still of grave concern in West Africa epicentre: WHO
GENEVA: Top Ebola experts on Thursday raised grave
concerns about the worsening epidemic in West Africa as the number of infections
soared to almost 10,000 and the death toll edged closer to 4,900.
The World Health Organisation said after an emergency
meeting on the deadly haemorrhagic fever that the situation in the worst-hit
countries of Guinea, Liberia and Sierra Leone remains of great concern as cases
A total of 976 cases have come in the last seven days
alone, said Isabelle Nuttall, head of the UN agency’s alert division. WHO said
the outbreak remains a public health emergency of international concern.
It formally declared a global emergency in August,
sparking outside criticism and internal soul-searching over claims that it was
too slow, as the first case was in Guinea in December.
WHO’s deputy chief, Keiji Fukuda, said the
international community had for months been ramping up the fight, with 600
international experts deployed in the embattled region over recent weeks.
Its 70/70 plan aims by December to ensure 70 per cent
of people infected by Ebola are placed in medical isolation, and, given that
dead bodies can spread the virus, to ensure 70 per cent of burials are
“By the beginning of December, we hope to see a bend
in the curve. It’s clear that it remains quite a challenge right now,” Fukuda
said. He pointed to major efforts to “break the chain of transmission” by
setting up special Ebola wards to try to save the lives of those struck by the
virus and stem fresh infections.
“But it has been terrifically difficult to get enough
health workers - both domestic health workers as well as international health
workers - and this continues to be one of the major challenges,” he said.
Health workers have paid a heavy price, with 244
deaths out of 443 cases across the affected countries. The hunt is on for a
vaccine, with supplies of Canadian-discovered experimental vaccine RVSV
arriving in Geneva for a new round of trials.
Hopes are also centred on ChAd3, an experimental
vaccine made by British company GlaxoSmithKline. Whichever proves its mettle in
trials, WHO hopes to deploy tens of thousands of doses to Africa by early 2015
for ‘real-world’ tests.
WHO held closed-door talks on Thursday on the issue of
access to and financing vaccines, as officials said costs could be in the ‘hundreds
of millions’ of dollars.
At a meeting on Thursday the European Union
fast-tracked 24.4 million Euros ($31 million) to find vaccines and treatments. “We’re
in a race against time on Ebola and we must address both the emergency
situation and at the same time have a long term response,” said EU chief Jose
Stemming Ebola in Guinea, Liberia and Sierra Leone
remains the top priority, the WHO said. Besides battling Ebola within their
borders with “leadership, community engagement, bringing in more partners,
paying staff on time, and accountability”, exit screening of air, land and sea
travellers remains critical, it said.
The agency reiterated its opposition to any general
ban on travel or trade with the region, saying it would pile on more economic
hardship and raise the risk of “uncontrolled migration of people from affected
countries, raising the risk of international spread of Ebola.”